Opinion

Video

Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.

  • What challenges do you anticipate in maintaining high treatment adherence rates for psoriasis therapies?
  • With increasing availability of targeted biologic therapies, how do you anticipate treatment strategies for psoriasis will continue to evolve?
Related Videos
Christine Funke, MD
5 experts are featured in this series
5 experts are featured in this series
1 expert in this video
1 expert in this video
Dr Margrit Wiesendanger
4 experts are featured in this series.
5 experts in this video
4 experts are featured in this series.
5 experts in this video
Related Content
AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com
May 21st 2025

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

Laura Joszt, MA Eileen Peng, PharmD
The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Among patients in the real-world setting, acalabrutinib was associated with reduced risks of AF or flutter and a reduced risk of hypertension. | Image credit: inthasone - stock.adobe.com
May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

AJMC Contributor
The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Hospital exterior | Image Credit: Spiroview Inc. - stock.adobe.com
May 16th 2025

Access to Minimally Invasive Surgery for Advanced Ovarian Cancer Varies Widely by Facility

Brooke McCormick
Facility-level disparities in adopting minimally invasive interval debulking surgery for ovarian cancer highlight urgent needs for equitable care access.
FDA headquarters | Image Credit: Tada Images - stock.adobe.com
May 16th 2025

Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer

Brooke McCormick
The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported by data from the POD1UM-303/InterAACT2 and POD1UM-202 trials.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo